Alpha-MSH Analogue Implants for XP DNA Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Xeroderma Pigmentosum (XP) are inadequate in enhancing DNA repair and reducing symptoms associated with the disorder, particularly in response to UV-induced DNA damage.
Innovation Solution
The use of alpha-MSH analogue compounds with agonist activity for the melanocortin-1-receptor (MC1R) receptor, administered in a controlled release composition to enhance UV-induced DNA repair in XP patients, specifically targeting complementation groups A, B, C, E, F, and V.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for XP are used, then treatment is provided, but DNA repair enhancement is inadequate and symptoms are not sufficiently reduced
Solution Approach 1:
The patent applies parameter changes by modifying the natural alpha-MSH molecule to create analogue compounds with enhanced properties. Specifically, the patent uses compounds like Afamelanotide which have altered amino acid sequences (e.g., substitution of Phe7 with D-Phe) to improve stability and agonist activity at the MC1R receptor, thereby enhancing DNA repair capability in XP patients beyond what natural alpha-MSH can achieve
2Reliability
If alpha-MSH analogue compounds are administered to enhance DNA repair, then DNA repair is improved, but maintaining adequate plasma levels requires controlled release mechanisms
Solution Approach 1:
The patent applies preliminary action through controlled release implant devices that are pre-loaded with alpha-MSH analogue compounds. These implants (such as subcutaneous rods) are implanted beforehand and automatically release the medication over extended periods (e.g., 5-15 days), eliminating the need for frequent patient visits and manual administration while maintaining therapeutic plasma levels
Solution Approach 2:
The patent uses controlled release mechanisms as intermediaries between the alpha-MSH analogue compound and the patient's system. The implant device acts as a mediator that regulates the release rate of the compound, ensuring stable plasma concentrations without requiring direct frequent administration by the patient
3Duration of action of moving object
If extended release composition is used to maintain plasma levels, then treatment duration is extended, but dosing frequency and monitoring requirements increase
Solution Approach 1:
The patent implements periodic action through controlled release implants that provide sustained drug delivery over specific time intervals (e.g., 5, 10, or 15 days). The implant releases the alpha-MSH analogue compound at controlled rates over this period, and after depletion, the implant is removed and replaced in a subsequent visit, creating a regular but low-frequency dosing schedule that balances duration of action with ease of operation
Data Source
AI summary
The present invention relates to alpha-MSH analogue compounds for treatment of Xeroderma Pigmentosum (XP), specifically for repairing DNA in a subject suffering from XP.